Austrianova’s Thai Subsidiary Signs Agreement With Thailand Science Park For Lab And Office Facilities Near Bangkok

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

March 7, 2014 -- Austrianova anno unced today that it s wholly owned Thai subsidiary , that was established last year , has signed an agreement with Thai land Science Park (TSP) to rent lab oratory and of fice space on the TSP campus just outside of Bangkok. The TSP is a state of the art, newly custom built , hi -- tech campus that houses around 60 leading internationa l biotech and Pharma companies and thus is an ideal location for Austrianova’s activities. Thailand was chosen as the location for the facilities because of that country’s commitment to making TSP a life sciences hub for all of Southeast Asia, as well as the well -- educated workforce and econ omic in centives by the Thai government. Thailand is a founding member of ASEAN, the Association of Southeast Asian Nations.

“We are pleased to announce the expansion of Austrianova into Thailand and the recruitment of our first two Thai employees ” said Austrianova Chairman Walter H. Gunzburg. “ Acquiring lab and office space at TSP is important for us since t his is the first step in establishing the GMP compliant production of encapsulated cell products for clinical trials. One of Austrianova’s strategic partners f or these studies is the listed U.S. biotech company , Nuvilex Inc .”

“Austrianova is now located at two premier South East Asian hubs , Biopolis in Singapore and Thailand Science Park in Bangkok, as well as having a presence in the U . K . , Germany and Austria, reflecting the global nature of our activities ” said Brian Salmons, C

About Austrianova

Austrianova is a biotech company that utilizes a proprietary , novel living cell encapsulation technology for mammalian (“Cell -- in -- a -- Box ® ") an d bacterial ( “Bac -- in -- a -- Box ® ”) cells . Cell -- in -- a -- Box ® protects the encapsulated living cells from rejection by the immune system, allows cells to be easily transported, stored and implanted at specific sites in patients. T he technology, which has been proven safe in clinical trials carried out in Europe, allows companies to develop one generic cell line for use as a living pharmaceutical in all patients suffering from a particular disease. Bac -- in -- a -- Box ® is a similar protective device for probiotic and other b acteria.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC